DOCSLIB.ORG

Olanzapine-Related Repetitive Focal Seizures with Lingual Dystonia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Olanzapine-Related Repetitive Focal Seizures with Lingual Dystonia Journal Identification = EPD Article Identification = 0805 Date: February 22, 2016 Time: 2:23 pm Clinical commentary with video sequence Epileptic Disord 2016; 18 (1): 83-6 Olanzapine-related repetitive focal seizures with lingual dystonia Francesca Anzellotti, Margherita Capasso, Valerio Frazzini, Marco Onofrj SS Annunziata Hospital of Chieti- Neurology, Chieti, Abruzzo, Italy Received July 20, 2015; Accepted January 09, 2016 ABSTRACT – Olanzapine-related seizures have rarely been reported despite associated proconvulsant risk factors described in the literature: myoclonic status, increased frequency of seizures, tonic-clonic seizures, as well as fatal status epilepticus. We present a psychiatric patient who developed repeti- tive focal motor seizures and lingual dystonia when olanzapine was added for psychomotor agitation and aggressiveness. Olanzapine was immedi- ately suspended and the seizures progressively disappeared. A control EEG showed no paroxysmal discharges. Olanzapine shares some phar- macological similarities with clozapine, a neuroleptic with a high risk of dose-dependent seizures. This adverse effect should be taken into account, and olanzapine should be used with caution if concomitant circumstances decrease the seizure threshold. [Published with video sequence online] Key words: olanzapine, side effect, seizure, focal motor seizure, lingual dystonia, EEG Atypical antipsychotics are known to (Grover et al., 2015; Williams and be associated with EEG abnormali- Park, 2015), whereas olanzapine ties (Centorrino et al., 2002). Olan- has infrequently been associated zapine is an atypical antipsychotic with relevant epileptogenic risk medication with fewer reported although it can lower seizure thresh- side effects than the traditional old (Woolley and Smith, 2001). antipsychotic agents. This drug has Earlier reports of the epilepto- considerable affinity for dopamine, genic risk associated with olan- serotonin, histamine, and adrener- zapine might have been poten- gic and muscarinic receptors (Fulton tially confounded by the presence and Goa, 1997). Structurally, it is of other medical disorders, pre- VIDEOS ONLINE a thienobenzodiazepine derivative, existing seizure disorders, or drug with pharmacological profile simi- withdrawal. We report the first doc- Correspondence: lar to that of clozapine, the first umented case of repetitive focal SS Annunziata Hospital of Chieti, atypical agent developed. Despite motor seizures with lingual dys- Neurology, Via Dei Vestini, their similarities, clozapine has been tonia induced by olanzapine in a Chieti 66023, Italy noted to induce dose-dependent patient with epilepsy and psychiatric <[email protected]> doi:10.1684/epd.2016.0805 seizures in about 5-6% of patients disorder. Epileptic Disord, Vol. 18, No. 1, March 2016 83 Journal Identification = EPD Article Identification = 0805 Date: February 22, 2016 Time: 2:23 pm F. Anzellotti, et al. Case study repetitive episodes of right mouth deviation, eyelid myoclonia, and aphasia. These episodes were briefly A 47-year-old man was brought to the emergency followed by oral and left hand gestural automatisms. department for psychotic episodes consisting of delu- Neurological examination was normal, with the excep- sions, agitation and mood changes. Patient medical tion of dysartria and mild extrapyramidal signs. Several history revealed a diagnosis of paranoid subtype investigations were performed (full blood count, ery- schizophrenia and post-traumatic seizure disorder throcyte sedimentation rate, liver function tests, serum since 16 years old; he fell off a bike with ictal episodes creatinine, prothrombin time, partial thromboplastin characterized by nocturnal hypermotor seizures. He time, thyroxine and antithyroid antibodies, folic acid, regularly took topiramate at 300 mg/day and pheno- and vitamin B12) and were normal. The ictal video-EEG barbital at 150 mg/day. He was first hospitalised in a revealed a clear correlation of symptoms with focal non-neurological department where he was treated spikes and polyspike discharges (figure 1). The EEG with olanzapine, 10 mg daily. After five days, he recording showed a left fronto-temporal focus with abruptly developed persistent dysartria with intermit- recruiting polyspikes, followed by generalized spike- tent eyelid myoclonia. As the cerebral tomography wave complexes at 4-5 Hz with phase opposition on (CT), as well as the interictal EEG, did not show any T3 and T4. A generalized frequency reduction of about significant abnormality, these episodes were at first 7-8 Hz was then recorded, and finally a focal epileptic interpreted as pseudoseizures and the patient was activity derived from the left fronto-temporal region treated with olanzapine, 15 mg daily.After two days, the was recorded. Clinically, we observed a right devia- patient was admitted to our neurological department tion of the mouth and eyelid myoclonia for about one due to sudden appearance of lingual dystonia, with minute, followed by gestural automatism of the left AC TM-RF TM-RF Fp2-F8 Fp2-F8 F8-T4 F8-T4 T4-T6 T4-T6 T6-O2 T6-O2 Fp2-F4 Fp2-F4 F4-C4 F4-C4 C4-P4 C4-P4 P4-O2 P4-O2 T4-C4 T4-C4 Fp1-F7 Fp1-F7 F7-T3 F7-T3 T3-T5 T3-T5 T5-O1 T5-O1 Fp1-F3 Fp1-F3 F3-C3 F3-C3 C3-P3 C3-P3 P3-O1 P3-O1 T3-C3 T3-C3 Fz-Cz Fz-Cz Cz-Pz Cz-Pz EKG EKG EOG EOG MK-RF MK-RF B D TM-RF TM-RF Fp2-F8 Fp2-F8 F8-T4 F8-T4 T4-T6 T4-T6 T6-O2 T6-O2 Fp2-F4 Fp2-F4 F4-C4 F4-C4 C4-P4 C4-P4 P4-O2 P4-O2 T4-C4 T4-C4 Fp1-F7 Fp1-F7 F7-T3 F7-T3 T3-T5 T3-T5 T5-O1 T5-O1 Fp1-F3 Fp1-F3 F3-C3 F3-C3 C3-P3 C3-P3 P3-O1 P3-O1 T3-C3 T3-C3 Fz-Cz Fz-Cz Cz-Pz Cz-Pz EKG EKG EOG EOG MK-RF MK-RF Figure 1. EEG recording showed a left fronto-temporal focus with recruiting polyspikes (A), followed by generalized spike-wave complexes at 4-5 Hz with phase opposition on T3 and T4 (B, C); finally a focal theta epileptic activity derived from the left fronto-temporal region was recorded (D). 84 Epileptic Disord, Vol. 18, No. 1, March 2016 Journal Identification = EPD Article Identification = 0805 Date: February 22, 2016 Time: 2:23 pm Olanzapine-related seizures and lingual dystonia hand (video sequence). No loss of consciousness was et al., 2000; Hedges and Jeppson, 2002). During the developed; during the seizure episode, the patient was last few years, two retrospective studies have been able to understand simple commands even if he was conducted which compared EEG effects of typical unable to talk. He was also able to remember the ictal and atypical neuroleptics in the psychiatric population and interictal events after seizure cessation. Although (Centorrino et al., 2002; Amann et al., 2003). Although his medical history documented the appearance of clozapine showed the greatest impact on EEG, both seizures after a head trauma, cranial MRI was nor- groups found that EEG epileptiform abnormality was mal. Due to the close temporal relationship between unusually high with olanzapine (35-38.5%), moderate seizures and olanzapine administration, this medica- with typical antipsychotics, and low with quetiap- tion was immediately interrupted and seizures were ine. Olanzapine has been described to be associated managed with diazepam at 1 mg three times daily. with seizures and status epilepticus; generalized and The patient was started on quetiapine at 50 mg/day, myoclonic seizures have been described with olanza- and the other medications were continued. Within pine in two patients with neuropsychiatric disorders, the next 36 hours, the seizures subsided and a con- namely, Huntington disease and Alzheimer disease trol EEG confirmed the absence of epileptic discharge, (Bonelli, 2003; Camacho et al., 2005). A few reports and psychotic symptoms progressively improved. At associate olanzapine with myoclonus; Camacho et al. discharge, the patient’s behavioural symptoms were (2005) described a case of myoclonic status induced by well controlled and he was seizure-free. olanzapine. This patient developed spontaneous and action-induced myoclonus in the trunk and extrem- ities within 48 hours of starting the drug. The jerks Discussion subsided within 36 hours after olanzapine was sus- pended. Deshauer et al. (2000) described a case of Seizures have been associated with both typical and combined olanzapine/clomipramine treatment result- atypical antipsychotic medications. Olanzapine is a ing in myoclonic jerks in their patients on two very effective antipsychotic with the advantage of occasions which progressed to generalized motor fewer side effects than typical neuroleptics, espe- seizures on one of these two occasions. Woolley and cially with regard to extrapyramidal symptoms. The Smith (2001) described an epileptic woman with para- main adverse reactions are somnolence, weight gain, noid psychosis whose seizure frequency increased glucose intolerance, and asymptomatic transaminase when switched from zuclopenthixol to olanzapine. elevation (Beasley et al., 1997). Like other antipsychotic Even though one report describes a dramatic case agents, it may lower the seizure threshold, provoking ending in fatal status epilepticus (Wyderski et al., epileptic activity. According to Lilly Research Labora- 1999), the remaining literature reports cases where tories, olanzapine showed a 0.9% (22/2,500) seizure seizure activity could be controlled either by olanza- incidence in premarketing testing. Olanzapine is a pine discontinuation or by concurrent antiepileptic thiobenzodiazepine derivative and shares pharma- drugs. Although there were confounding factors in cological properties with clozapine (Schuld et al., some
Load more

Recommended publications
  • Current P SYCHIATRY
    Current p SYCHIATRY N ew Investigators Tips to manage and prevent discontinuation syndromes Informed tapering can protect patients when you stop a medication Sriram Ramaswamy, MD Shruti Malik, MBBS, MHSA Vijay Dewan, MD Instructor, department of psychiatry Foreign medical graduate Assistant professor Creighton University Department of psychiatry Omaha, NE University of Nebraska Medical Center Omaha, NE bruptly stopping common psychotropics New insights on psychotropic A —particularly antidepressants, benzodi- drug safety and side effects azepines, or atypical antipsychotics—can trigger a discontinuation syndrome, with: This paper was among those entered in the 2005 • rebound or relapse of original symptoms Promising New Investigators competition sponsored • uncomfortable new physical and psycho- by the Neuroleptic Malignant Syndrome Information Service (NMSIS). The theme of this year’s competition logical symptoms was “New insights on psychotropic drug safety and • physiologic withdrawal at times. side effects.” To increase health professionals’ awareness of URRENT SYCHIATRY 1 C P is honored to publish this peer- the risk of these adverse effects, this article reviewed, evidence-based article on a clinically describes discontinuation syndromes associated important topic for practicing psychiatrists. with various psychotropics and offers strategies to NMSIS is dedicated to reducing morbidity and anticipate, recognize, and manage them. mortality of NMS by improving medical and psychiatric care of patients with heat-related disorders; providing
    [Show full text]
  • Doxepin Exacerbates Renal Damage, Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Urinary Chromium Loss in Obese Mice
    pharmaceuticals Article Doxepin Exacerbates Renal Damage, Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Urinary Chromium Loss in Obese Mice Geng-Ruei Chang 1,* , Po-Hsun Hou 2,3, Wei-Cheng Yang 4, Chao-Min Wang 1 , Pei-Shan Fan 1, Huei-Jyuan Liao 1 and To-Pang Chen 5,* 1 Department of Veterinary Medicine, National Chiayi University, 580 Xinmin Road, Chiayi 60054, Taiwan; [email protected] (C.-M.W.); [email protected] (P.-S.F.); [email protected] (H.-J.L.) 2 Department of Psychiatry, Taichung Veterans General Hospital, 1650 Taiwan Boulevard (Section 4), Taichung 40705, Taiwan; [email protected] 3 Faculty of Medicine, National Yang-Ming University, 155 Linong Street (Section 2), Taipei 11221, Taiwan 4 School of Veterinary Medicine, National Taiwan University, 1 Roosevelt Road (Section 4), Taipei 10617, Taiwan; [email protected] 5 Division of Endocrinology and Metabolism, Show Chwan Memorial Hospital, 542 Chung-Shan Road (Section 1), Changhua 50008, Taiwan * Correspondence: [email protected] (G.-R.C.); [email protected] (T.-P.C.); Tel.: +886-5-2732946 (G.-R.C.); +886-4-7256166 (T.-P.C.) Abstract: Doxepin is commonly prescribed for depression and anxiety treatment. Doxepin-related disruptions to metabolism and renal/hepatic adverse effects remain unclear; thus, the underlying mechanism of action warrants further research. Here, we investigated how doxepin affects lipid Citation: Chang, G.-R.; Hou, P.-H.; change, glucose homeostasis, chromium (Cr) distribution, renal impairment, liver damage, and fatty Yang, W.-C.; Wang, C.-M.; Fan, P.-S.; liver scores in C57BL6/J mice subjected to a high-fat diet and 5 mg/kg/day doxepin treatment for Liao, H.-J.; Chen, T.-P.
    [Show full text]
  • Ecstasy and the Concomitant Use of Pharmaceuticals
    J.Copeland, P. Dillon & M. Gascoigne Ecstasy and the Concomitant Use of Pharmaceuticals NDARC Technical Report No. 201 ECSTASY AND THE CONCOMITANT USE OF PHARMACEUTICALS Jan Copeland (PhD), Paul Dillon & Michael Gascoigne Technical Report Number 201 ISBN: 1 877027 92 8 ©National Drug and Alcohol Research Centre, University of New South Wales, Sydney, 2004 This work is copyright. You may download, display, print and reproduce this material in unaltered form only (retaining this notice) for your personal, non-commercial use or use within your organisation. All other rights are reserved. Requests and enquiries concerning reproduction and rights should be addressed to the information manager, National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW 2052, Australia. 2 ACKNOWLEDGEMENT This study and report was funded by the Australian Government Department of Health and Ageing’s National Illicit Drug Strategy. It was conducted concurrently with a study of aspects of information seeking among ecstasy users and there is some replication of the data presented on demographic characteristics and perception of ecstasy related harms in this Technical Report and Technical Report Number 202. 3 TABLE OF CONTENTS ACKNOWLEDGEMENT 3 TABLE OF CONTENTS 4 TABLE OF TABLES 5 EXECUTIVE SUMMARY 6 INTRODUCTION 7 Anti-depressant medication 8 5-hydroxytryptophan 9 Attention Deficit Hyperactivity Disorder 11 Sildenafil Citrate 12 Benzodiazepines 13 Study Ains 14 METHOD 15 Participants 15 Procedure 15 Measures 15 RESULTS 17 Demographics
    [Show full text]
  • Olanzapine-Induced Acute Pancreatitis and New Diabetes Mellitus
    Open Journal of Psychiatry, 2012, 2, 110-112 OJPsych http://dx.doi.org/10.4236/ojpsych.2012.22015 Published Online April 2012 (http://www.SciRP.org/journal/ojpsych/) Case report: Olanzapine-induced acute pancreatitis and new diabetes mellitus Erik Monasterio1*, Ruchi Bhalla2, Andrew McKean3 1Department of Psychological Medicine, University of Otago, Christchurch, New Zealand 2Hammersmith and Fulham Mental Health Unit, West London Mental Health NHS Trust, London, UK 3Hillmorton Hospital, Christchurch, New Zealand Email: *[email protected] Received 29 December 2011; revised 31 January 2012; accepted 15 February 2012 ABSTRACT criteria and required application from a psychiatrist for a patient who had been trialled unsuccessfully on risperi- The aim of this case study is to review the literature done or required treatment with olanzapine short acting and report the first published case of olanzapine-in- intra-muscular injection [4]. In June 2011, significantly duced acute pancreatitis in New Zealand. A case re- cheaper generic versions of olanzapine were introduced port of acute pancreatitis with new onset diabetes and the special authority criteria for olanzapine with- mellitus secondary to olanzapine in a 42-year-old male, drawn [5]. We aim to highlight lesser known and poten- in the absence of medical risk factors is reported. tially fatal side effects through our case report. Eleven previous case reports of olanzapine induced acute-pancreatitis were identified in the literature. A 2. CASE REPORT 42-year-old male was diagnosed with acute pancreati- tis and new diabetes mellitus induced by olanzapine. Mr. X is a 42 year old man who had come into contact Although rare, pancreatitis is associated with use of with mental health services on many occasions during some atypical antipsychotic medications.
    [Show full text]
  • Clopixol Acuphase®)
    Guidelines for the use of zuclopenthixol acetate injection (Clopixol Acuphase®) Version 3.1 – January 2018 GUIDELINE REPLACED Version 3 RATIFYING COMMITTEE Drugs and Therapeutics Group DATE RATIFIED October 2015 NEXT REVIEW DATE January 2021 EXECUTIVE SPONSOR Executive Medical Director ORIGINAL AUTHOR Jed Hewitt – Chief Pharmacist Review / update – 2015 Helen Manuell – Lead Pharmacist (ESx) Review / update - 2018 Jed Hewitt – Chief Pharmacist If you require this document in an alternative format, i.e. easy read, large text, audio or Braille please contact the pharmacy team on 01243 623349. Guidelines for the use of zuclopenthixol acetate injection (Clopixol Acuphase®) Introduction In the past, Acuphase® has often been too widely and possibly inappropriately used, sometimes without full regard being given to the fact that it is a potentially hazardous and toxic preparation with very little published information to support its use. Indeed, the Cochrane Library concludes that there is inadequate data on Acuphase® and no convincing evidence to support its use in acute psychiatric emergency. So far as possible, it should therefore be reserved for the minority of patients who have a prior history of previous use and good response, with use defined in an advance directive. Similarly, as a general rule Acuphase® should not be used for rapid tranquillisation unless such practice is also in accordance with an advance directive. Normally, Acuphase® should never be considered as a first-line drug for rapid tranquillisation as its onset of action will often not be rapid enough in these circumstances. In addition, the administration of an oil-based injection carries very high risk in a highly agitated patient.
    [Show full text]
  • CENTRAL NERVOUS SYSTEM DEPRESSANTS Opioid Pain Relievers Anxiolytics (Also Belong to Psychiatric Medication Category) • Codeine (In 222® Tablets, Tylenol® No
    CENTRAL NERVOUS SYSTEM DEPRESSANTS Opioid Pain Relievers Anxiolytics (also belong to psychiatric medication category) • codeine (in 222® Tablets, Tylenol® No. 1/2/3/4, Fiorinal® C, Benzodiazepines Codeine Contin, etc.) • heroin • alprazolam (Xanax®) • hydrocodone (Hycodan®, etc.) • chlordiazepoxide (Librium®) • hydromorphone (Dilaudid®) • clonazepam (Rivotril®) • methadone • diazepam (Valium®) • morphine (MS Contin®, M-Eslon®, Kadian®, Statex®, etc.) • flurazepam (Dalmane®) • oxycodone (in Oxycocet®, Percocet®, Percodan®, OxyContin®, etc.) • lorazepam (Ativan®) • pentazocine (Talwin®) • nitrazepam (Mogadon®) • oxazepam ( Serax®) Alcohol • temazepam (Restoril®) Inhalants Barbiturates • gases (e.g. nitrous oxide, “laughing gas”, chloroform, halothane, • butalbital (in Fiorinal®) ether) • secobarbital (Seconal®) • volatile solvents (benzene, toluene, xylene, acetone, naptha and hexane) Buspirone (Buspar®) • nitrites (amyl nitrite, butyl nitrite and cyclohexyl nitrite – also known as “poppers”) Non-Benzodiazepine Hypnotics (also belong to psychiatric medication category) • chloral hydrate • zopiclone (Imovane®) Other • GHB (gamma-hydroxybutyrate) • Rohypnol (flunitrazepam) CENTRAL NERVOUS SYSTEM STIMULANTS Amphetamines Caffeine • dextroamphetamine (Dexadrine®) Methelynedioxyamphetamine (MDA) • methamphetamine (“Crystal meth”) (also has hallucinogenic actions) • methylphenidate (Biphentin®, Concerta®, Ritalin®) • mixed amphetamine salts (Adderall XR®) 3,4-Methelynedioxymethamphetamine (MDMA, Ecstasy) (also has hallucinogenic actions) Cocaine/Crack
    [Show full text]
  • Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics
    pharmaceutics Review Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics Francisco José Toja-Camba 1,2,† , Nerea Gesto-Antelo 3,†, Olalla Maroñas 3,†, Eduardo Echarri Arrieta 4, Irene Zarra-Ferro 2,4, Miguel González-Barcia 2,4 , Enrique Bandín-Vilar 2,4 , Victor Mangas Sanjuan 2,5,6 , Fernando Facal 7,8 , Manuel Arrojo Romero 7, Angel Carracedo 3,9,10,* , Cristina Mondelo-García 2,4,* and Anxo Fernández-Ferreiro 2,4,* 1 Pharmacy Department, University Clinical Hospital of Ourense (SERGAS), Ramón Puga 52, 32005 Ourense, Spain; [email protected] 2 Clinical Pharmacology Group, Institute of Health Research (IDIS), Travesía da Choupana s/n, 15706 Santiago de Compostela, Spain; [email protected] (I.Z.-F.); [email protected] (M.G.-B.); [email protected] (E.B.-V.); [email protected] (V.M.S.) 3 Genomic Medicine Group, CIMUS, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain; [email protected] (N.G.-A.); [email protected] (O.M.) 4 Pharmacy Department, University Clinical Hospital of Santiago de Compostela (SERGAS), Citation: Toja-Camba, F.J.; 15706 Santiago de Compostela, Spain; [email protected] Gesto-Antelo, N.; Maroñas, O.; 5 Department of Pharmacy and Pharmaceutical Technology and Parasitology, University of Valencia, Echarri Arrieta, E.; Zarra-Ferro, I.; 46100 Valencia, Spain González-Barcia, M.; Bandín-Vilar, E.; 6 Interuniversity Research Institute for Molecular Recognition and Technological Development,
    [Show full text]
  • Olanzapine and Clozapine Increase the Gabaergic Neuroactive Steroid Allopregnanolone in Rodents
    Neuropsychopharmacology (2003) 28, 1–13 & 2003 Nature Publishing Group All rights reserved 0893-133X/03 $25.00 www.neuropsychopharmacology.org Olanzapine and Clozapine Increase the GABAergic Neuroactive Steroid Allopregnanolone in Rodents ,1 2,3 2 2 2,3,4 Christine E Marx* , Margaret J VanDoren , Gary E Duncan , Jeffrey A Lieberman and A Leslie Morrow 1Department of Psychiatry and Behavioral Sciences, Duke University Medical Center and Durham VA Medical Center, Durham, North Carolina, USA; 2Department of Psychiatry, University of North Carolina, Chapel Hill, North Carolina 27599, USA; 3Center for Alcohol Studies, University of 4 North Carolina, Chapel Hill, North Carolina 27599, USA; Department of Pharmacology, University of North Carolina, Chapel Hill, North Carolina 27599, USA The neuroactive steroid allopregnanolone is a potent g-aminobutyric acid type A (GABAA) receptor modulator with anxiolytic and anticonvulsant effects. Olanzapine and clozapine also have anxiolytic-like effects in behavioral models. We therefore postulated that olanzapine and clozapine would elevate allopregnanolone levels, but risperidone and haloperidol would have minimal effects. Male rats received intraperitoneal olanzapine (2.5–10.0 mg/kg), clozapine (5.0–20.0 mg/kg), risperidone (0.1–1.0 mg/kg), haloperidol (0.1–1.0 mg/ kg), or vehicle. Cerebral cortical allopregnanolone and peripheral progesterone and corticosterone levels were determined. Adrenalectomized animals were also examined. Both olanzapine and clozapine increased cerebral cortical allopregnanolone levels, but neither risperidone nor haloperidol had significant effects. Olanzapine and clozapine also increased serum progesterone and corticosterone levels. Adrenalectomy prevented olanzapine- and clozapine-induced elevations in allopregnanolone. Allopregnanolone induction may contribute to olanzapine and clozapine anxiolytic, antidepressant, and mood-stabilizing actions.
    [Show full text]
  • Antipsychotic Codes Used from Drug Programs Information Network (DPIN) Database
    Antipsychotic Codes Used from Drug Programs Information Network (DPIN) Database Drug Identification Anatomical Therapeutic Chemical Equivalent Generic Product Name Product Description Number (DIN) (ATC) Drug Classification HALOPERIDOL INJECTION 17574 HALDOL INJECTION 5MG/ML N05AD01 HALOPERIDOL TRIFLUOPERAZINE HCL 21865 NOVO-FLURAZINE TAB 2MG N05AB06 TRIFLUOPERAZINE TRIFLUOPERAZINE HCL 21873 NOVO-FLURAZINE TAB 5MG N05AB06 TRIFLUOPERAZINE TRIFLUOPERAZINE HCL 21881 NOVO-FLURAZINE TAB 10MG N05AB06 TRIFLUOPERAZINE THIORIDAZINE 27375 MELLARIL SUS 10MG/5ML N05AC02 THIORIDAZINE FLUPHENAZINE ENANTHATE 29173 MODITEN ENANTHATE INJ 25MG/ML N05AB02 FLUPHENAZINE THIORIDAZINE HYDROCHLORIDE 37486 NOVO-RIDAZINE 50MG N05AC02 THIORIDAZINE THIORIDAZINE HYDROCHLORIDE 37494 NOVO-RIDAZINE 25MG N05AC02 THIORIDAZINE THIORIDAZINE HYDROCHLORIDE 37508 NOVO-RIDAZINE 10MG N05AC02 THIORIDAZINE CHLORPROMAZINE HCL 232157 NOVO-CHLORPROMAZINE TAB 10MG N05AA01 CHLORPROMAZINE CHLORPROMAZINE HCL 232807 NOVO-CHLORPROMAZINE TAB 50MG N05AA01 CHLORPROMAZINE CHLORPROMAZINE HCL 232823 NOVO-CHLORPROMAZINE TAB 25MG N05AA01 CHLORPROMAZINE CHLORPROMAZINE HCL 232831 NOVO-CHLORPROMAZINE TAB 100MG N05AA01 CHLORPROMAZINE LITHIUM CARBONATE 236683 CARBOLITH CAP 300MG N05AN01 LITHIUM TRIFLUOPERAZINE HCL 312746 APO TRIFLUOPERAZINE TAB 5MG N05AB06 TRIFLUOPERAZINE TRIFLUOPERAZINE HCL 312754 APO TRIFLUOPERAZINE TAB 2MG N05AB06 TRIFLUOPERAZINE PIMOZIDE 313815 ORAP TAB 2MG N05AG02 PIMOZIDE PIMOZIDE 313823 ORAP TAB 4MG N05AG02 PIMOZIDE TRIFLUOPERAZINE HCL 326836 APO TRIFLUOPERAZINE TAB 10MG N05AB06
    [Show full text]
  • Guidance on the Treatment of Antipsychotic Induced Hyperprolactinaemia in Adults
    Guidance on the Treatment of Antipsychotic Induced Hyperprolactinaemia in Adults Version 1 GUIDELINE NO RATIFYING COMMITTEE DRUGS AND THERAPEUTICS GROUP DATE RATIFIED April 2014 DATE AVAILABLE ON INTRANET NEXT REVIEW DATE April 2016 POLICY AUTHORS Nana Tomova, Clinical Pharmacist Dr Richard Whale, Consultant Psychiatrist In association with: Dr Gordon Caldwell, Consultant Physician, WSHT . If you require this document in an alternative format, ie easy read, large text, audio, Braille or a community language, please contact the Pharmacy Team on 01243 623349 (Text Relay calls welcome). Contents Section Title Page Number 1. Introduction 2 2. Causes of Hyperprolactinaemia 2 3. Antipsychotics Associated with 3 Hyperprolactinaemia 4. Effects of Hyperprolactinaemia 4 5. Long-term Complications of Hyperprolactinaemia 4 5.1 Sexual Development in Adolescents 4 5.2 Osteoporosis 4 5.3 Breast Cancer 5 6. Monitoring & Baseline Prolactin Levels 5 7. Management of Hyperprolactinaemia 6 8. Pharmacological Treatment of 7 Hyperprolactinaemia 8.1 Aripiprazole 7 8.2 Dopamine Agonists 8 8.3 Oestrogen and Testosterone 9 8.4 Herbal Remedies 9 9. References 10 1 1.0 Introduction Prolactin is a hormone which is secreted from the lactotroph cells in the anterior pituitary gland under the influence of dopamine, which exerts an inhibitory effect on prolactin secretion1. A reduction in dopaminergic input to the lactotroph cells results in a rapid increase in prolactin secretion. Such a reduction in dopamine can occur through the administration of antipsychotics which act on dopamine receptors (specifically D2) in the tuberoinfundibular pathway of the brain2. The administration of antipsychotic medication is responsible for the high prevalence of hyperprolactinaemia in people with severe mental illness1.
    [Show full text]
  • List Item Olanzapine Teva
    EMA/685358/2012 EMEA/H/C/000810 EPAR summary for the public Olanzapine Teva olanzapine This is a summary of the European public assessment report (EPAR) for Olanzapine Teva. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Olanzapine Teva. What is Olanzapine Teva? Olanzapine Teva is a medicine containing the active substance olanzapine. It is available as tablets (2.5, 5, 7.5, 10, 15 and 20 mg) and as ‘orodispersible’ tablets (5, 10, 15 and 20 mg). Orodispersible tablets are tablets that dissolve in the mouth. Olanzapine Teva is a ‘generic medicine’. This means that Olanzapine Teva is similar to ‘reference medicines’ already authorised in the European Union (EU) called Zyprexa and Zyprexa Velotab. For more information on generic medicines, see the question-and-answer document here. What is Olanzapine Teva used for? Olanzapine Teva is used to treat adults with schizophrenia. Schizophrenia is a mental illness that has a number of symptoms including disorganised thinking and speech, hallucinations (hearing or seeing things that are not there), suspiciousness and delusions (mistaken beliefs). Olanzapine Teva is also effective in maintaining improvement in patients who have responded to an initial course of treatment. Olanzapine Teva is also used to treat moderate to severe manic episodes (extremely high mood) in adults. It can also be used to prevent the recurrence of these episodes (when symptoms come back) in adults with bipolar disorder (a mental illness causing alternating periods of high mood and depression) who have responded to an initial course of treatment.
    [Show full text]
  • ARISTADA INITIO® Prescribing Information
    HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ___________________ CONTRAINDICATIONS ___________________ ARISTADA INITIO® safely and effectively. See full prescribing Known hypersensitivity to aripiprazole (4). information for ARISTADA INITIO®. _______________ WARNINGS AND PRECAUTIONS _______________ ARISTADA INITIO® (aripiprazole lauroxil) extended-release injectable • Cerebrovascular Adverse Reactions in Elderly Patients with Dementia- suspension, for intramuscular use Related Psychosis: Increased incidence of cerebrovascular adverse Initial U.S. Approval: 2015 reactions (e.g., stroke, transient ischemia attack, including fatalities) (5.2). • Potential for Dosing and Medication Errors: Substitution and dispensing WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS errors between ARISTADA INITIO and ARISTADA could occur. Do not WITH DEMENTIA-RELATED PSYCHOSIS substitute ARISTADA INITIO for ARISTADA (5.3). See full prescribing information for complete boxed warning. • Neuroleptic Malignant Syndrome: Manage with immediate discontinuation and close monitoring (5.4). • Elderly patients with dementia-related psychosis treated with • Tardive Dyskinesia: Discontinue if clinically appropriate (5.5). antipsychotic drugs are at an increased risk of death. (5.1) • Metabolic Changes: Monitor for hyperglycemia, dyslipidemia, and weight • ARISTADA INITIO is not approved for the treatment of patients with gain (5.6). dementia-related psychosis. (5.1) • Pathological Gambling and Other Compulsive Behaviors:
    [Show full text]